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Purpose: The aim of this study was to investigate the differences of expression in 
glycolysis-related proteins such as Glut-1, carbonic anhydrase (CA) IX, and mono-
carboxylate transporter (MCT) 4 according to the myoepithelial cell (MEC) and 
basement membrane (BM) status in solid papillary carcinoma (SPC) of the breast. 
Materials and Methods: Immunohistochemical evaluation of Glut-1, CAIX, and 
MCT4, as well as p63 and type IV collagen, were performed on 23 SPC cases. Re-
sults: Six and nine cases of SPC showed the presence and absence of myoepithelial 
cells, respectively, and eight cases belonged to the borderline status (p63-positive 
MEC on some areas of the outer tumor surface but not in others). BM was partially 
or completely absent in 14 cases and present in nine cases. SPC lacking BM more 
frequently showed high expression of CAIX than SPC with BM (p=0.037). Conclu-
sion: In SPC of the breast, a strong expression of CAIX seems to be associated with 
an increasing degree of loss of BM, which can be interpreted as BM degradation due 
to the induction of extracellular acidity with increasing expression of CAIX.
Key Words:   Basement membrane, breast, metabolism, myoepithelial cell, solid 
papillary carcinoma
INTRODUCTION
 
Solid papillary carcinoma (SPC) of the breast, which was first described by Maluf 
and Koerner,1 occurs mainly in elderly women and was considered as a variant of 
ductal carcinoma in situ (DCIS) in its first description. Histologically, SPC is com-
posed of circumscribed, solid nodules of tumor cells, which are typically ovoid and 
spindle shaped, with intervening network of fibrovascular cores but without a dis-
crete papillary structure.1 The tumor cells can exhibit neuroendocrine features, in-
cluding granular eosinophilic cytoplasm and fine nuclear chromatin, as well as im-
munohistochemical expression of chromogranin and synaptophysin.1,2 Though 
SPC was considered as a variant of DCIS when first described, it has subsequently 
been suggested that SPC showing a lack of myoepithelial cells (MEC) in the pe-
riphery of a tumor nodule might instead be a subset of invasive carcinoma with 
pushing margin.2,3 Additionally, the possibility of SPC as an invasive carcinoma is 
further supported by the occurrence of regional lymph node metastasis in SPC.2 
Although there are a number of possible processes involved in the progression 
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by breast pathologists (Kwon JE, Koo JS). SPC was de-
fined histologically as follows: circumscribed, solid nod-
ules of tumor cells, which are typically ovoid and spindle 
shaped, with an intervening network of fibrovascular cores 
but without a discrete papillary structure.1 When extracellu-
lar mucin was observed in SPC-like tumors, we diagnosed 
mucinous carcinoma if tumor cells floated on mucin pools. 
Otherwise, we defined it as SPC. Cases in which other types 
of carcinoma were identified were excluded. A total of 37 
cases of SPC were collected from the pathology depart-
ment. Fourteen cases which were mixed type tumors were 
excluded from the study; mixed with mucinous carcinoma 
in 8 cases and with usual invasive ductal carcinoma in 6 cas-
es. Histological examination was performed using H&E-
stained slides. The histological grade was assessed using 
the Nottingham grading system.8 This study was approved 
by the Institutional Review Board (IRB) of Yonsei Univer-
sity Severance Hospital. All experiments were performed in 
compliance with institutional guidelines. Informed consents 
from patients were exempt by IRB.
Immunohistochemistry
The antibodies used for immunohistochemistry in this 
study are shown in Table 1. All immunostains were per-
formed using formalin-fixed, paraffin-embedded tissue sec-
tions. Using a microtome, 5-μm-thick sections were ob-
tained, transferred to adhesive slides, and dried at 62°C for 
30 minutes. The sections were then placed in a glass jar with 
10 mM citrate buffer (pH 6.0) and irradiated in a microwave 
oven for 15 min. The sections were allowed to cool in the 
jar at room temperature for 20 min. The slides were then 
rinsed with Tris buffered saline (TBS). A blocking reagent 
was added for 10 min after quenching the endogenous per-
oxidase activity in 0.3% hydrogen peroxide for 10 min. After 
incubation with the primary antibodies, immunodetection 
from DCIS to invasive carcinoma during breast cancer tu-
morigenesis, Gatenby and Gillies4 have described the meta-
bolic process as a cellular adaptation with three phases: hy-
poxia, glycolysis, and acidosis. Regional hypoxia occurs 
when tumor cells move away from the basement membrane 
owing to cellular proliferation within a duct, consequently in-
ducing an adaptive upregulation of glycolysis. Due to intra-
cellular acidosis caused by glycolysis with lactate produc-
tion, the tumor cells require resistance to acid-induced 
toxicity. Upregulation of glycolysis and subsequent cellular 
resistance to acid, which together confer a powerful adaptive 
advantage, allow for unlimited proliferation of tumor cells 
and eventually function as selection forces in the transition 
process from a preinvasive lesion to an invasive cancer. Dur-
ing glycolysis in tumor cells, the Glut-1 protein is critical for 
glucose uptake into cells,5 and the carbonic anhydrase (CA) 
IX enzyme has an important role in the elimination of glycol-
ysis-related acidosis, regulating pH by reverse hydration of 
carbon dioxide to carbonic acid.6 Additionally, monocarbox-
ylate transporter (MCT) 4 plays a role in the efflux of lactate 
produced by glycolysis out of the tumor cells.7
We hypothesize that there may be some differences in 
glycolysis and/or acid resistance between SPCs with and 
without invasion. The aim of this study was to investigate 
differences in glycolysis and acid resistance according to 
MEC and basement membrane (BM) status in SPC using 
immunohistochemical detection of Glut-1 and CAIX. 
MATERIALS AND METHODS
　　　
Patient selection and clinicopathologic analysis
This study included patients undergoing surgical resection 
of SPC at Severance Hospital from January 2005 to De-
cember 2011. All of the cases were retrospectively reviewed 
Table 1. Clone, Dilution, and Source of Study Antibodies
Antibody Clone Dilution Company
ER SP1   1:100 Thermo Scientific, CA, USA
PR PgR 1:50 DAKO, Denmark
HER-2 Polyclonal     1:1500 DAKO, Denmark
Glut-1 SPM498   1:200 Abcam, Cambridge, UK
CAIX Polyclonal   1:100 Abcam, Cambridge, UK
MCT4 H-90   1:100 Santa Cruz, CA, USA
p63 EPR5701   1:800 Abcam, Cambridge, UK
Type IV collagen Polyclonal   1:250 Abcam, Cambridge, UK
Chromogranin A Polyclonal   1:100 Abcam, Cambridge, UK
Synaptophysin SY38 1:50 Abcam, Cambridge, UK
ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor 2; CAIX, carbonic anhydrase IX; MCT, monocarboxylate transporter.
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Immunohistochemical staining results for Glut-1, CAIX, 
MCT4 were defined by the proportion of positively stained 
cells as follows: negative=no staining; low positive=less 
than 50% of tumor cells stained; high positive=50% or 
more of tumor cells stained. Chromogranin A and synapto-
physin was considered positive when more than 10% of tu-
mor cells were expressed. MEC status at the outer surface 
of SPC was evaluated by p63 immunostaining. Using nor-
mal duct or acini in the background as positive control, the 
presence of p63-positive MEC covering the entire outer sur-
face was defined as “MEC present,” and the absence of p63-
positive MEC covering the entire outer surface as “MEC 
absent.” When p63-positive MEC were found on some ar-
eas of the outer tumor surface but not in others, it was de-
fined as “MEC indefinite.” To identify the presence of BM, 
immunohistochemical staining for type IV collagen was 
used. With the positive control of normal duct or acini in 
the background, clear linear expression of type IV collagen 
on the outer surface of the SPC was considered BM posi-
tive, and otherwise was considered BM negative. 
Statistical analysis
Data were processed using SPSS for Windows, version 
12.0 (SPSS Inc., Chicago, IL, USA). Student’s t and Fish-
er’s exact tests were used to evaluate differences in continu-
ous and categorical variables, respectively. Statistical signif-
icance was defined as a p-value less than 0.05.
was performed with biotinylated antimouse immunoglobu-
lin, followed by peroxidase-labeled streptavidin using a la-
beled streptavidin biotin kit with 3,3’-diaminobenzidine 
chromogen as substrate. Optimal primary antibody incuba-
tion time and concentration were determined via serial dilu-
tion for each immunohistochemical assay with an identical-
ly fixed and embedded tissue block.
Interpretation of immunohistochemical staining
All immunohistochemical markers were assessed using 
light microscopy. Pathologic parameters such as estrogen 
receptor (ER), progesterone receptor (PR), and human epi-
dermal growth factor 2 (HER-2) status were obtained from 
patient report. A cut-off value of 1% positively stained nuclei 
was used to define ER and PR positivity.9 HER-2 staining 
was analyzed according to the guidelines of the American 
Society of Clinical Oncology/College of American Patholo-
gists using the following categories: 0=no immunostaining; 
1+=weak incomplete membranous staining, less than 10% 
of tumor cells; 2+=complete membranous staining, either 
uniform or weak in at least 10% of tumor cells; and 3+=uni-
form intense membranous staining in at least 30% of tumor 
cells. HER-2 immunostaining was considered positive when 
strong (3+) membranous staining was observed, whereas 
cases with 0 to 1+ were regarded as negative.10 The cases 
showing 2+ HER-2 expression were evaluated for HER-2 
amplification by fluorescent in situ hybridization.
Table 2. Patient Characteristics According to Combined Myoepithelial Cell and Basement Membrane Status
Parameters 
Total 
n=23 (%)
Myoepithelial cell and basement membrane status in outer surface
p valueMEC* (+)/BM (+) 
n=7 (%)
MEC* (+)/BM (-) 
n=7 (%)
MEC*/BM (+) 
n=2 (%)
MEC*/BM (-) 
n=7 (%)
Age (yrs, mean±SD) 57.1±13.4 57.3±14.8 56.5±15.7 50.5±2.1 59.5±12.8 0.882
Tumor size (cm, mean±SD) 1.6±0.5 1.7±0.5 1.5±0.5   1.5±0.2 1.8±0.6 0.771
Estrogen receptor n/a
    Positive   23 (100.0)     7 (100.0)     7 (100.0)     2 (100.0)     7 (100.0)
    Negative 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Progesterone 0.655
    Positive 19 (82.6)   6 (85.7)   6 (85.7)   1 (50.0)   6 (85.7)
    Negative   4 (17.4)   1 (14.3)   1 (14.3)   1 (50.0)   1 (14.3)
HER-2 0.939
    0 12 (52.2)   4 (57.1)   4 (57.1)   1 (50.0)   3 (42.9)
    1+   9 (39.1)   2 (28.6)   3 (42.9)   1 (50.0)   3 (42.9)
    2+ 2 (8.7)   1 (14.3) 0 (0.0) 0 (0.0)   1 (14.3)
Mucin production 0.431
    No 16 (69.6)   6 (85.7)   4 (57.1)     2 (100.0)   4 (57.1)
    Yes   7 (30.4)   1 (14.3)   3 (42.9) 0 (0.0)   3 (42.9)
MEC, myoepithelial cells; BM, basement membrane; HER-2, human epidermal growth factor 2.
*p63 indefinite cases were considered MEC (+). 
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type IV collagen. Out of 9 cases without MEC on the outer 
surface, 7 (77.8%) cases were negative for type IV collagen.
Expression of glycolysis-related proteins according to 
combined MEC and BM status
Both MEC (+)/BM (-) and MEC (-)/BM (-) cases had high-
er CAIX positivity than MEC (+)/BM (+) and MEC (-)/BM 
(+) cases, although these were not statistically significant 
differences (p=0.059) (Table 3).  
Expression of glycolysis-related proteins by MEC status
There was no significant difference in other factors between 
SPC with MEC at the outer surface and SPC without. Stro-
mal MCT4 expression was noted only in p63-negative or 
indefinite cases (Table 4). 
Expression of glycolysis-related proteins according to 
BM status
CAIX expression was increased in SPC lacking BM (p= 
0.037) (Table 5, Fig. 1). There was a trend that SPC lacking 
BM had a higher rate of mucin production. 
RESULTS
 
Clinicopathologic characteristics according to 
combined MEC and BM status
A total of 23 patients were included in the study (Table 2). 
The mean age of enrolled patients was 57.1±13.4 years, 
and the mean size of tumor was 1.6±0.5 cm. All cases were 
ER-positive, and 19 cases (82.6%) were also PR-positive. 
Immunostaining for HER-2 was negative in 21 cases, and 
no amplification was detected in either of the two cases 
with 2+ immunopositivity for HER-2 by fluorescence in 
situ hybridization. Mucin production was noted in 7 cases 
(30.4%). Sentinel lymph node examination was performed 
in 10 out of 23 patients; none of the cases showed lymph 
node involvement or distant metastasis. There was no dif-
ference in clinicopathologic characteristics according to 
combined MEC and BM status.
The absence of MEC on the outer surface was correlated 
with negative type IV collagen (p=0.036). Among 6 cases with 
MEC on the outer surface, 5 (83.3%) cases were positive for 
Table 3. Expression of Glycolysis-Related Proteins According to Combined Myoepithelial Cell and Basement Membrane Status
Parameters 
Total 
n=23 (%)
Myoepithelial cell and basement membrane status in outer surface
p valueMEC* (+)/BM (+)
n=7 (%)
MEC* (+)/BM (-)
n=7 (%)
MEC* (-)/BM (+)
n=2 (%)
MEC*(-)/BM (-)
n=7 (%)
Glut-1 0.550
    Negative 17 (73.9)   6 (85.7)   6 (85.7)   1 (50.0)   4 (57.1)
    Low   4 (17.4)   1 (14.3) 0 (0.0)   1 (50.0)   2 (28.6)
    High 2 (8.7) 0 (0.0)   1 (14.3) 0 (0.0)   1 (14.3)
CAIX 0.059
    Negative   9 (39.1)   4 (57.1)   2 (28.6) 0 (0.0)   3 (42.9)
    Low   5 (21.7)   2 (28.6)   1 (14.3)     2 (100.0) 0 (0.0)
    High   9 (39.1)   1 (14.3)   4 (57.1) 0 (0.0)   4 (57.1)
MCT4 0.615
    Negative   9 (39.1)   3 (42.9)   3 (42.9) 0 (0.0)   3 (42.9)
    Low   9 (39.1)   4 (57.1)   2 (28.6)   1 (50.0)   2 (28.6)
    High   5 (21.7) 0 (0.0)   2 (28.6)   1 (50.0)   2 (28.6)
MCT4 in stroma 0.662
    Negative 18 (78.3)   6 (85.7)   6 (85.7)   1 (50.0)   5 (71.4)
    Positive                      5 (21.7)   1 (14.3)   1 (14.3)   1 (50.0)   2 (28.6)
Chromogranin 0.102
    Negative 14 (60.9)   4 (57.1)   2 (28.6)     2 (100.0)   6 (85.7)
    Positive   9 (39.1)   3 (42.9)   5 (71.4) 0 (0.0)   1 (14.3)
Synaptophysin 0.886
    Negative 15 (65.2)   4 (57.1)   5 (71.4)   1 (50.0)   5 (71.4)
    Positive   8 (34.8)   3 (42.9)   2 (28.6)   1 (50.0)   2 (28.6)
MEC, myoepithelial cells; BM, basement membrane; MCT, monocarboxylate transporter.
*p63 indefinite cases were considered MEC (+). 
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Table 4. Expression of Glycolysis-Related Proteins According to Myoepithelial Cell Status
Parameters 
Total 
n=23 (%)
Myoepithelial cell status in outer surface
p value
Present, n=6 (%) Indefinite, n=8 (%) Absent, n=9 (%)
Glut-1 0.392
    Negative 17 (73.9)   5 (83.3)   7 (87.5) 5 (55.6)
    Low   4 (17.4)   1 (16.7) 0 (0.0) 3 (33.3)
    High 2 (8.7) 0 (0.0)   1 (12.5) 1 (11.1)
CAIX 0.730
    Negative   9 (39.1)   3 (50.0)   3 (37.5) 3 (33.3)
    Low   5 (21.7)   2 (33.3)   1 (12.5) 2 (22.2)
    High   9 (39.1)   1 (16.7)   4 (50.0) 4 (44.4)
MCT4 0.813
    Negative   9 (39.1)   2 (33.3)   4 (50.0) 3 (33.3)
    Low   9 (39.1)   3 (50.0)   3 (37.5) 3 (33.3)
    High   5 (21.7)   1 (16.7)   1 (12.5) 3 (33.3)
MCT4 in stroma 0.297
    Negative 18 (78.3)     6 (100.0)   6 (75.0) 6 (66.7)
    Positive   5 (21.7) 0 (0.0)   2 (25.0) 3 (33.3)
Chromogranin 0.078
    Negative 14 (60.9)   3 (50.0)   3 (37.5) 8 (88.9)
    Positive   9 (39.1)   3 (50.0)   5 (62.5) 1 (11.1)
Synaptophysin 0.980
    Negative 15 (65.2)   4 (66.7)   5 (62.5) 6 (66.7)
    Positive   8 (34.8)   2 (33.3)   3 (37.5) 3 (33.3)
MCT, monocarboxylate transporter.
Table 5. Expression of Glycolysis-Related Proteins According to Basement Membrane Status
Parameters 
Total 
n=23 (%)
Basement membrane status
p value
Negative, n=14 (%) Positive, n=9 (%)
Glut-1 0.469
    Negative 17 (73.9) 10 (71.4)   7 (77.8)
    Low   4 (17.4)   2 (14.3)   2 (22.2)
    High 2 (8.7)   2 (14.3) 0 (0.0)
CAIX 0.037
    Negative   9 (39.1)   5 (35.7)   4 (44.4)
    Low   5 (21.7) 1 (7.1)   4 (44.4)
    High   9 (39.1)   8 (57.1)   1 (11.1)
MCT4 0.384
    Negative   9 (39.1)   6 (42.9)   3 (33.3)
    Low   9 (39.1)   4 (28.6)   5 (55.6)
    High   5 (21.7)   4 (28.6)   1 (11.1)
MCT4 in stroma 0.964
    Negative 18 (78.3) 11 (78.6)   7 (77.8)
    Positive   5 (21.7)   3 (21.4)   2 (22.2)
Chromogranin 0.648
    Negative 14 (60.9)   8 (57.1)   6 (66.7)
    Positive   9 (39.1)   6 (42.9)   3 (33.3)
Synaptophysin 0.435
    Negative 15 (65.2) 10 (71.4)   5 (55.6)
    Positive   8 (34.8)   4 (28.6)   4 (44.4)
MCT, monocarboxylate transporter.
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face of SPC, labeled by p63 immunostaining, was signifi-
cantly correlated with type IV collagen status (p=0.036). In 
other words, if the outer surface of SPC lacked MEC, BM 
was also absent, suggesting that, in SPC, alteration of MEC 
is accompanied by the loss of BM. On the other hand, there 
was a small subset of SPC with only one positive feature, 
either MEC (-)/BM (+) or MEC (+)/BM (-). This finding is 
consistent with previous reports of DCIS in which intact 
BM was identified in spite of a loss of MEC,12,13 as well as 
other reports of invasive ductal carcinoma which secreted a 
DISCUSSION
This study investigated the expression of glycolysis-related 
protein in SPC categorized by MEC and/or BM status as 
markers of invasiveness. As to the invasiveness in SPC, 
there have been inconsistencies in previous studies, some 
of which reported the absence of MEC in SPC,1,3 and others 
of which reported the presence of MEC in SPC.11 
In the present study, the presence of MEC at the outer sur-
Fig. 1. Expression of glycolysis-related proteins according to myoepithelial cell and basement membrane status. In situ SPC shows p63-
positive myoepithelial cells in the outer surface of the tumor nodule (arrow) and a basement membrane that is positive for type IV colla-
gen (arrow). Indefinite SPC shows p63 negativity on one side and p63-positive myoepithelial cells at the outer surface of the other side of 
the tumor nodule and is negative for type IV collagen. In invasive SPC, both p63 and type IV are negative at the outer surface of the tumor 
nodule. SPC which is negative for type IV collagen shows a high level of CAIX expression, and invasive carcinoma shows high level of 
MCT4 expression in the stroma (S) as well as tumor cells (T). SPC, solid papillary carcinoma; MCT, monocarboxylate transporter; CAIX, 
carbonic anhydrase IX.
In situ Borderline Invasive
Type IV collagen
H&E
CAIX
p63
MCT4
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increased. Increased CAIX level, possibly associated with 
acquisition of acid-resistance of the tumor cells, may lead 
to extracellular acidity and subsequent BM degradation.
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